KRAS and gastric cancer: We performed pharmacogenomics analysis using a gastric cancer cell line panel and discovered a causal linkage cascade of oncogenic KRAS mutation, aberrant CCNA2 upregulation and hypersensitivity to PLK1 inhibitors.